KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Share-based Compensation (2017 - 2025)

Twist Bioscience (TWST) has disclosed Share-based Compensation for 9 consecutive years, with $13.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 10.69% to $13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.7 million through Dec 2025, up 26.68% year-over-year, with the annual reading at $64.5 million for FY2025, 26.58% up from the prior year.
  • Share-based Compensation for Q4 2025 was $13.3 million at Twist Bioscience, down from $16.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $22.5 million in Q1 2022, with the low at -$2.3 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $13.4 million, with a median of $12.8 million recorded in 2024.
  • The sharpest move saw Share-based Compensation tumbled 112.84% in 2022, then skyrocketed 573.98% in 2023.
  • Over 5 years, Share-based Compensation stood at $18.1 million in 2021, then tumbled by 112.84% to -$2.3 million in 2022, then surged by 573.98% to $11.0 million in 2023, then rose by 8.81% to $12.0 million in 2024, then increased by 10.69% to $13.3 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $13.3 million, $16.1 million, and $16.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.